Skip to main content
GENB logo

GENB · Generate Biomedicines, Inc. · Holdings

Track GENB — free
$9.54 -0.83 (-8.00%) At close · Nov 20
Market Cap
$1.23B
Shares
129.10M
Volume · Nov 20 967.86K Avg daily vol (3M) 1.23M

Institutional ownership from SEC Form 13F filings. Investment managers with more than $100 million in U.S. equities must disclose their positions every quarter, within 45 days of quarter-end, so the holdings shown can lag the market by up to a quarter.

Holders: 109
Total Value: $1,603,257,581
Total Shares: 106,741,521
+ 2,094,616 shares withheld under SEC confidential treatment, last reported; not in the totals
Showing 1–100 of 110 holdings by value · page 1 of 2

Institutional Ownership Trend

3 quarters

A holder reported that quarter and withheld its positions under SEC confidential treatment, which is not a sale. The line counts it at the shares it last reported; filers usually disclose the real figures about a year later.

Holder Concentration

Share of 13F common-share value, across 109 filers with any position, options included · Δ vs Jun 30, 2026
Top Holder
58.7%
Mar 2026 → Sep 2026 · range 58.7% – 67.5%
−3.9 pts
Top 5
74.6%
Mar 2026 → Sep 2026 · range 74.6% – 83.4%
−2.9 pts
Top 10
84.5%
Mar 2026 → Sep 2026 · range 84.5% – 92.4%
−1.9 pts
HHI
3,555
Mar 2026 → Sep 2026 · range 3,555 – 4,643
Highly concentrated−457

Who Holds GENB

Last 3 quarters through Sep 30, 2026

Each kind of 13F filer's share of the common shares 13F filers report. Holder type comes from regulatory records, never the filer's name; style, turnover and horizon are measured from each filer's own 13F book. The quarter selector does not change this card.

Sep 30, 2026: 109 filers, like-for-like change +9.0%; actively managed books +7.7%; index-like books +33.4%.

Holder type Share Filers Change
Registered adviser 14.3% 46 +24.0%
Exempt adviser 60.7% 4 -0.3%
Adviser 6.4% 4 +20.3%
Bank 3.6% 14 +37.7%
Broker-dealer 0.0% 1 new
Benefit plan 0.0% 1 -93.5%
Non-US 0.2% 3 +77.1%
Holding company 9.1% 5 +33.1%
Unknown 5.7% 31 +27.5%
How the mix is measured

Shares are 13F common shares restated to today's split basis; options and principal amounts are left out. The change compares only filers with a 13F in both quarters and keeps each filer in its bucket of the later quarter on both sides; a filer that continues under a new CIK is compared through its successor. Holder type comes from each filer's current regulatory profile; client base and private funds come from the Form ADV roster current at each quarter end (rosters from December 2019, so an earlier quarter reads Unknown). Style, turnover, horizon and book size are measured from each filer's 13F book in the newest measured quarter, and Not measured means none was. Actively managed books are those measured systematic-like, concentrated or diversified active.

Excluded 2 holders with no observed 2026-09-30 13F.

Conviction and Crowding

109 13F filers, quarter ended Sep 30, 2026

Measured across every 13F filer's common-share book once the quarter's filing window closed. Crowding counts filers with high turnover or that advise private funds on Form ADV.

Conviction holders
3
2.75% of filers hold it in their top 10
Jun 30, 2026: 4
Holders above 5%
2
median weight 0.001%
Jun 30, 2026: 2
Crowding
59.6%
of shares outstanding, 99th percentile
Jun 30, 2026: 58.4%
Private-fund advisers
59.3%
of shares outstanding
Institutional ownership
83.2%
181.2% of the estimated free float above 100%: filers can report lent or client shares more than once
Top 10 holders
84.5%
of 13F shares, Herfindahl 0.355
Active holders
+7.7%
like-for-like share change of active filers
5% stakes on record
3
0 13D, 3 13G (1 institutional, 0 passive, 2 exempt)
How long holders have held it value-weighted 2.9 quarters
Under 1 year 100.0% 1 to 3 years 0.000% 3 years or more 0.000% Since coverage start 0.000%

Managers in the top fifth by current three-year FundScore alpha were net buyers of $23,042,840 (5 buying, 3 selling).

Estimated Holder Cost Basis

Quarter ended Sep 30, 2026, on that quarter's share basis

Estimated, never filed: each 13F buy is costed at its quarter's average traded price and each sale keeps the average cost, so this is what holders paid on average if they traded evenly through each quarter.

Estimated avg cost
$12.65
estimated per share
Jun 30, 2026: $12.33
Quarter-end price
$15.02
implied by 13F values
Estimated gain or loss
+18.8%
price against the estimated cost
Estimated at a loss
4.80%
of costed 13F value

Estimated cost covers 97.7% of the 13F shares; positions already held when a filer's 13F history starts, or bought in a quarter without a trusted average price, have no estimate.

Shared Holders

Companies GENB's active holders also own, quarter ended Sep 30, 2026
# Company Shared holders
1 AVTX Avalo Therapeutics, Inc. 5
2 RACD Research Alliance Corp IV 3
3 COAG Hemab Therapeutics Holdings, Inc. 3
4 SPTX Seaport Therapeutics, Inc. 3
5 AKTS Aktis Oncology, Inc. 3
6 GHRS GH Research PLC 3
7 SANA Sana Biotechnology, Inc. 3
8 JTTT JATT III Acquisition Corp 3
9 NRIX Nurix Therapeutics, Inc. 5
10 MAZE Maze Therapeutics, Inc. 4

Shareholder Targets

13F filers that own its peers but not GENB, quarter ended Sep 30, 2026

Found through its holder-overlap peers: AVTX, RACD, COAG, SPTX, AKTS, GHRS, SANA, JTTT, NRIX, MAZE, XENE, NMRA, DSGN, RAPP, SLDB, TYRA, BEAM, RLAY, XFOR, ZURA. 614 filers in all.

# Filer In peers
1 RA CAPITAL MANAGEMENT, L.P. Registered adviser, Concentrated $768,426,908 8 held
2 T. Rowe Price Investment Management, Inc. Adviser, Diversified active $747,220,876 5 held
3 PERCEPTIVE ADVISORS LLC Registered adviser, Diversified active $507,368,251 7 held
4 SB INVESTMENT ADVISERS (UK) LTD Registered adviser, Concentrated $395,384,582 1 held
5 JANUS HENDERSON GROUP PLC Adviser, Diversified active $392,414,502 13 held
6 Casdin Capital, LLC Registered adviser, Concentrated $355,767,115 4 held
7 FARALLON CAPITAL MANAGEMENT LLC Registered adviser, Diversified active $346,146,686 4 held
8 Avoro Capital Advisors LLC Registered adviser, Concentrated $340,916,673 4 held
9 BVF INC/IL Unknown, Concentrated $319,789,877 5 held
10 Lynx1 Capital Management LP Registered adviser, Concentrated $311,576,835 2 held

Fund Ownership of GENB by Fund Type

Registered funds' Form N-PORT reports for the quarter ended Jun 30, 2026

Index funds and index ETFs hold 1.75% of shares outstanding.

Fund type Of shares outstanding Shares
Index funds 0.21% 265,100
Index ETFs 1.55% 1,997,042
Active ETFs 0.39% 503,595
Active funds 5.33% 6,881,250
Unclassified 0.21% 266,290
All registered funds 7.68% 9,913,277
How fund types are measured

Each fund series counts once, with its latest Form N-PORT report dated inside the quarter; only long share positions count, restated to today's split basis. The fund type is the series' latest Form N-CEN answer on or before the quarter end (the index-fund box and the exchange-traded flag), never its name. Unclassified funds have no usable N-CEN; unit investment trusts are among them, so index ownership is a floor. Funds sit inside their advisers' 13F reports, so these shares overlap the 13F figures and are never added to them.

Quarterly Activity

vs Jun 30, 2026
New
35
Increased
36
Decreased
17
Sold Out
10
Unchanged
21

New and Sold Out count only filers that reported a 13F for both quarters: a first-time filer's book is not a buy, and a fund that has not filed, or withheld its positions under confidential treatment, has not sold.

Holder count: +23
Institutional value: -5.0%
Shares held: +6.7%

Institutional value and shares held compare the totals as filed: 2,094,616 shares reported for Jun 30, 2026 by holders that withheld this quarter are left out, and that part of the change is not a sale.

Top Buyers

vs Jun 30, 2026
Institution Added Now Holds Open

Top Sellers

vs Jun 30, 2026
Institution Sold Now Holds Open

Top New Positions

vs Jun 30, 2026
Institution Acquired Value (USD) Open

Top Sold-Out Positions

vs Jun 30, 2026
Institution Previously Held Last Value (USD) Open
Showing 100 of 110
Export CSV
Holder Value (USD) % of 13F Shares Own % Change Type Filed Open

Showing the top 100 of 110 holders. Create a free account to see every holder, past quarters, search, filters and CSV export.

Key facts CIK 2100782 CUSIP 370920100 13F (30d) 100 filings 98 filers Visit website Investor relations